Article
CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions.
Pharmacogenomics - 1 Jul 2013
Kuo Hsiang-Wei, Liu Shu Chih, Tsou Hsiao-Hui, Liu Sheng-Wen, Lin Keh-Ming, Lu Shao-Chun, Hsiao Mei-Chun, Hsiao Chin-Fu, Liu Chia-Yih, Chen Chia-Hui, Lu Mong-Liang, Shen Winston W, Tang Hwa-Sheng, Liu Shen-Ing, Chang Liang-Huey, Wu Hsiao-Yu, Chang Yao-Sheng, Yeh Teng-Kuang, Chen Andrew Ch, Liu Yu-Li
Abstract excerpt
AIM: The liver CYP1A2 enzyme may metabolize antidepressant escitalopram (S-CIT) to S-desmethylcitalopram (S-DCIT) and S-didesmethylcitalopram (S-DDCIT). This study tested whether genetic polymorphisms in the CYP1A2 gene are associated with the treatment responses to S-CIT. MATERIALS & METHODS: Ten SNPs in CYP1A2 were selected and genotyped in 158 patients under S-CIT treatment. The serum levels of S-CIT and its...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.